Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.41 USD | +0.12% | 0.00% | -19.06% |
06-17 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
06-17 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
Evolution of the average Target Price on Zymeworks Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Zymeworks Inc.
Wells Fargo Securities | |
HC Wainwright | |
Citigroup | |
Stifel Nicolaus | |
JPMorgan Chase | |
SVB Securities LLC | |
Barclays | |
Jefferies & Co. | |
Guggenheim | |
Evercore ISI | |
SVB Leerink | |
Raymond James | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- ZYME Stock
- Consensus Zymeworks Inc.